To give additional context around our enhanced eCOA solution, sponsor partners have communicated the following differentiation and benefits of our technology platform:
EMAW is substantially differentiated in the market as larger, private equity backed companies – including legacy eCOA providers – often fail to deliver high quality and low cost solutions, especially for smaller sponsors with earlier phase trials. Further, we have highly active scientists as founders and scientific consultants. These founders have produced multiple poster presentations and written several papers with sponsors of our trials. Considerably more papers are in development as some of the large-scale trials on which we have worked have just completed.
Proud Member of ACNP</span
Sponsors generally recognize that older eCOA platforms use antiquated and/or have poorly integrated multiple disparate technologies. The result is that these platforms require different devices, divide data flows, cost a lot to maintain, operate at slow speeds, and embed too many patches. In addition to higher costs, this patchwork approach causes data errors and expanded timelines, not to mention the common need to manually merge data from these different platforms which leads to risk for more data errors, increases costs even more, and extends timelines considerably.
Because our platform has been built with a single code base and is accessible via a single downloadable application, it offers ultimate flexibility to sponsors looking to design traditional in clinic, remote or hybrid trials, using BYOD or fulfilled devices, collecting and monitoring all patient and clinician generated data, active (ePRO, eCLINRO, EMA) or passive.
The singular platform not only provides benefits around cost, speed and data security, but it also enables our teams to view clean data immediately, both separately and together comprehensively to further derive additional informed insights enhancing subject selection (adherence, consistently meeting entry criteria), precision measurement, meaningful change and separation from comparator treatments, and other longitudinal and contemporaneous insights. The FDA has already set the precedent of acknowledging power in shorter, smaller trials based on the bolus of digital and other real-world data collected.
Our Differentiation
- One integrated platform - One SSO / web-based application is downloaded across devices and operating systems with seamless data capture for in clinic, virtual, or hybrid trial designs and audio/video capture for quality assurance and reviews
- Speed and agility - Exponentially faster startup timelines with the agility to address protocol amendments in a few days which minimizes any study delays
- Cost - Savings from a scalable, purpose-built technology solution passed on to sponsors, enabling them to run more individual trials to get more shots on goal and drive their own enterprise value
- Patient / site centric - Single device, downloadable application, integrated training/ certification/ surveillance functions this means sites and users don’t need to use multiple devices which mitigates user and cost burden
We focus on Data - a singular system means data flows to the same place which:
- Reduces data errors
- Enables faster insights for contemporaneous data visualization;
- Facilitates end of trial data analysis without reorganization/re-entry;
- Enables automated flags/alerts for higher compliance;
- Simple storage architecture for data science / deeper analytics
- Drives better outcomes quality
- Enables smaller, faster trials
- Better quality control for interim and final reporting